艾曲泊帕联合环孢素A一线治疗成人重型再生障碍性贫血的活性与安全性(SOAR):一项2期单臂研究
SOAR是一项多中心单臂2期试验,在10个国家20家医院纳入54例未治疗的重型再生障碍性贫血成人患者,口服艾曲泊帕联合环孢素A治疗6个月,主要终点为意向治疗人群6个月总体血液学缓解率,结果为46%(25/54;95%CI 33-60),最常见不良事件为血清胆红素升高(22例[41%]),8例治疗期间死亡但均认为与治疗无关。
要点
- 6个月总体血液学缓解率为46%(25/54;95%CI 33-60)。
- 最常见不良事件为血清胆红素升高(22例[41%])和恶心(16例[30%])。
- 8例治疗期间死亡,但均认为与治疗无关。
核心结论
- 艾曲泊帕联合环孢素A作为重型再生障碍性贫血一线治疗具有活性,未发现非预期安全性问题。
- 作者认为在无法获得或不能耐受马源抗胸腺细胞球蛋白的情况下,该方案可能有益。
研究设计与样本
- SOAR为多中心、单臂2期试验,纳入成人(≥18岁)未治疗且东部肿瘤协作组体能状态评分小于2的重型再生障碍性贫血患者。
- 患者来自10个国家20家医院,共54例,于2017年5月11日至2020年3月23日入组。
- 艾曲泊帕起始150 mg(亚裔患者100 mg),环孢素A 10 mg/kg每日口服(调整至谷浓度200-400 μg/L),从第1天至6个月。
- 主要终点为意向治疗人群6个月时总体血液学缓解率;试验注册号NCT02998645,已完成。
主要发现
- 54例患者中34例(63%)为男性,20例(37%)为女性;22例(41%)为亚裔,22例(41%)为白人,1例(2%)为美洲原住民或阿拉斯加原住民,1例(2%)为黑人或非裔美国人,8例(15%)为其他种族或族裔。
- 35例(65%)完成6个月艾曲泊帕联合环孢素A治疗,6例(11%)完成至第24个月的环孢素A减量期。
- 6个月时总体血液学缓解率为46%(25/54;95%CI 33-60)。
- 最常见不良事件为血清胆红素升高(22例[41%])、恶心(16例[30%])、丙氨酸氨基转移酶浓度升高(12例[22%])和腹泻(12例[22%])。
- 8例患者治疗期间死亡,但无死亡认为与治疗相关。
关键数值与推荐
- 6个月总体血液学缓解率:46%(25/54;95%CI 33-60)。
- 艾曲泊帕起始剂量150 mg(亚裔患者100 mg),环孢素A 10 mg/kg每日(调整至谷浓度200-400 μg/L)。
临床怎么用
- 作者认为艾曲泊帕联合环孢素A作为重型再生障碍性贫血一线治疗具有活性,未发现非预期安全性问题。
- 作者认为在无法获得或不能耐受马源抗胸腺细胞球蛋白的情况下,该方案可能有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antithymocyte globulin (ATG)-based immunosuppression is standard in front-line treatment for people with severe aplastic anaemia without a histocompatible donor or who are 40 years or older. However, ATG requires in-hospital administration, is associated with infusion-related toxicities and has limited availability worldwide. In this study, we investigated the activity and safety of an ATG-free regimen of eltrombopag with cyclosporin A as a potential treatment for patients with severe aplastic anaemia who might not have access to or cannot tolerate horse-ATG. METHODS: SOAR was a multicentre, single-arm phase 2 trial investigating eltrombopag and cyclosporin in adult (≥18 years) patients with severe aplastic anaemia who were treatment-naive and had an Eastern Cooperative Oncology Group performance status of less than 2. Participants were recruited from 20 hospitals in ten countries. Eltrombopag was initiated at 150 mg (100 mg in patients of Asian ethnicity) and cyclosporin at 10 mg/kg per day (adjusted to a trough of 200-400 μg/L) orally from day 1 to 6 months. The primary outcome was an overall haematological response rate by 6 months in the intention-to-treat population. This is the final report of the primary analysis period. The trial was registered with ClinicalTrials.gov, NCT02998645, and has been completed. FINDINGS: 54 patients were enrolled between May 11, 2017, and March 23, 2020. 34 (63%) patients were male and 20 (37%) were female. 22 (41%) were Asian, 22 (41%) were White, one (2%) was Native American or Alaska Native, one (2%) was Black or African American, and eight (15%) were other race or ethnicity. 35 patients (65%) completed 6 months of treatment with eltrombopag and cyclosporin and six (11%) completed the cyclosporin tapering period up to month 24. Overall haematological response rate by month 6 of treatment was 46% (25 of 54; 95% CI 33-60). The most reported adverse events were increased serum bilirubin (in 22 patients [41%]), nausea (16 [30%]), increased alanine aminotransferase concentration (12 [22%]), and diarrhoea (12 [22%]). Eight patients died on-treatment, but no deaths were considered related to the treatment. INTERPRETATION: Eltrombopag and cyclosporin was active as front-line treatment of severe aplastic anaemia, with no unexpected safety concerns. This approach might be beneficial where horse-ATG is not available or not tolerated. FUNDING: Novartis Pharmaceuticals.
引用
- Scheinberg P, Finelli C, Montaňo-Figueroa EH, et al. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study. Lancet Haematol. 2024. PMID: 38335978. doi:10.1016/S2352-3026(23)00395-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。